A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
Roy, A.C., Park, S.R., Cunningham, D., Kang, Y.K., Chao, Y., Chen, L.T., Rees, C., Lim, H.Y., Tabernero, J., Ramos, F.J., Kujundzic, M., Cardic, M.B., Yeh, C.G., de Gramont, A.
Published in Annals of oncology (01.06.2013)
Published in Annals of oncology (01.06.2013)
Get full text
Journal Article